Patents Assigned to ISIS Pharmaceuticals Inc.
  • SUBSTITUTED 2'-AMINO AND 2'-THIO-BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
    Publication number: 20130131147
    Abstract: Provided herein are 2?-amino and 2?-thio bicyclic nucleosides and oligomenc compounds prepared therefrom. The novel bicyclic nucleosides provided herein are expected to be useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as nuclease resistance.
    Type: Application
    Filed: June 2, 2011
    Publication date: May 23, 2013
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Punit P. Seth, Thazha P. Prakash, Eric E. Swayze
  • MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
    Publication number: 20130123331
    Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.
    Type: Application
    Filed: August 3, 2012
    Publication date: May 16, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, Xing-Xian Yu, Brett P. Monia
  • Tetrahydropyran nucleic acid analogs
    Patent number: 8440803
    Abstract: The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: May 14, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Punit P. Seth
  • 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
    Publication number: 20130116420
    Abstract: The present invention provides 5? modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5?-substituent and an optional 2? substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: April 26, 2011
    Publication date: May 9, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • ANTISENSE MODULATION OF GCGR EXPRESSION
    Publication number: 20130116301
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GCGR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
    Type: Application
    Filed: September 20, 2012
    Publication date: May 9, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Isis Pharmaceuticals, Inc.
  • COMPOSITIONS AND THEIR USES DIRECTED TO ACEYTL-COA CARBOXYLASES
    Publication number: 20130109849
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 2, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Brett P. Monia, John G. Geisler, Robert McKay, Kenneth W. Dobie
  • MODIFIED 5' DIPHOSPHATE NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
    Publication number: 20130109850
    Abstract: Provided herein are modified 5? diphosphate nucleosides and oligomeric compounds prepared therefrom. More particularly, modified 5? diphosphate nucleosides are provided that can be further modified at the 2? and 5? positions. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The oligomeric compounds are also expected to be useful as primers and probes in diagnostic applications.
    Type: Application
    Filed: April 26, 2011
    Publication date: May 2, 2013
    Applicant: Isis Pharmaceuticals, Inc
    Inventors: Thazha P. Prakash, Punit P. Seth, Muthiah Manoharan, Eric E. Swayze, Kallanthottathil G. Rajeev, Ivan Zlatev
  • COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
    Publication number: 20130109091
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 2, 2013
    Applicants: Cold Spring Harbor Laboratory, Isis Pharmaceuticals, Inc.
    Inventors: Isis Pharmaceuticals, Inc., Cold Spring Harbor Laboratory
  • Oligomeric compounds comprising tricyclic nucelosides and methods for their use
    Patent number: 8426378
    Abstract: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: April 23, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Punit P. Seth, Thazha P. Prakash
  • Compositions and their uses directed to huntingtin
    Patent number: 8415465
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: April 9, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
    Publication number: 20130084576
    Abstract: The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: April 26, 2011
    Publication date: April 4, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Compositions and their uses directed to gemin genes
    Patent number: 8409856
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of a Gemin Gene. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: April 2, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Susan M. Freier
  • Modulation of eIF4E expression
    Patent number: 8410074
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: April 2, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION
    Publication number: 20130079387
    Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating or preventing conditions, including hyperproliferative conditions, associated with raf expression.
    Type: Application
    Filed: November 15, 2012
    Publication date: March 28, 2013
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventor: ISIS PHARMACEUTICALS, INC.
  • Positionally modified siRNA constructs
    Patent number: 8394947
    Abstract: The present invention provides oligomeric compounds having sufficient complementarity to hybridize to a nucleic acid target and methods for their use in modulating gene expression. In one embodiment the oligomeric compounds comprise double stranded constructs wherein one of the strands capable of hybridizing to a nucleic acid target, and has a plurality of modified ribofuranosyl nucleosides at defined locations. The presence of modifications at such defined positions greatly enhances the properties of the corresponding compositions.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: March 12, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Eric E. Swayze, Thazha P. Prakash, Charles Allerson, Prasad Dande, Richard H. Griffey
  • MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION
    Publication number: 20130059777
    Abstract: Compositions and methods are provided for decreasing blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of glucose-6-phosphatase translocase expression alone or in combination with at least one glucose-lowering drug. Also provided are compositions and methods for treating diabetes and other metabolic disorders.
    Type: Application
    Filed: July 30, 2012
    Publication date: March 7, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Kenneth W. Dobie
  • METHODS AND COMPOSITIONS USEFUL IN TREATMENT OF DISEASES OR CONDITIONS RELATED TO REPEAT EXPANSION
    Publication number: 20130059902
    Abstract: The present invention is drawn to chemically-modified oligomers that are complementary to, and capable of hybridizing within the repeat region of CAG, CUG, or CCUG nucleotide repeat-containing RNAs (NRRs).
    Type: Application
    Filed: February 8, 2011
    Publication date: March 7, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: David Corey, C. Frank Bennett, Eric E. Swayze, Keith Gagnon
  • Antidotes to antisense compounds
    Patent number: 8389488
    Abstract: The present invention relates to antisense antidote compounds and uses thereof. Such antidote compounds reduce the magnitude and/or duration of the antisense activity of an antisense compound.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: March 5, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Andrew M. Siwkowski, Hong Zhang
  • MODULATION OF CETP EXPRESSION
    Publication number: 20130053430
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a CETP mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or HDL activity and reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Application
    Filed: April 7, 2011
    Publication date: February 28, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Thomas A. Bell, III, Rosanne M. Crooke, Mark J. Graham
  • MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN-LIKE GROWTH FACTOR EXPRESSION
    Publication number: 20130053431
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Application
    Filed: October 18, 2012
    Publication date: February 28, 2013
    Applicants: Isis Pharmaceuticals, Inc., Antisense Therapeutics Limited
    Inventors: Antisense Therapeutics Limited, Isis Pharmaceuticals, Inc.